HDAC2-IN-4
HDAC2-IN-4 is a HDAC2 inhibitor with an IC50 of 4.2 nM against human HDAC2. HDAC2-IN-4 binds to the active site of HDAC2 via hydrogen bonding and hydrophobic interactions, forming a thermodynamically stable and kinetically compatible protein-ligand complex to inhibit enzymatic activity. HDAC2-IN-4 inhibits cancer cell proliferation and exhibits low toxicity to normal cells. HDAC2-IN-4 can be used in studies related to human endocervical adenocarcinoma and Burkitt lymphoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C19H28N2O5
- Masse moléculaire:364.44
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
IC50 & Target
[1]|
hHDAC2 4.2 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
5.07 μM
|
Antiproliferative activity against human endocervical adenocarcinoma HeLa cells assessed by resazurin assay after 72 h incubation with the compound followed by 3 h resazurin incubation.
Antiproliferative activity against human endocervical adenocarcinoma HeLa cells assessed by resazurin assay after 72 h incubation with the compound followed by 3 h resazurin incubation.
|
42520173 |
| Raji | IC50 |
1.87 μM
|
Antiproliferative activity against human Burkitt's lymphoma Raji cells assessed by resazurin assay after 72 h incubation with the compound followed by 3 h resazurin incubation.
Antiproliferative activity against human Burkitt's lymphoma Raji cells assessed by resazurin assay after 72 h incubation with the compound followed by 3 h resazurin incubation.
|
42520173 |
In Vitro
HDAC2-IN-4 (compound 23e) (0.1-100 μM; 1 h) potently inhibits purified human HDAC2 protein, with an IC50 of 4.2 nM[1].
HDAC2-IN-4 (500 ns) forms a thermodynamically stable and kinetically compatible complex with human HDAC2 protein[1].
HDAC2-IN-4 (0.1-250 μM; 72 h) potently inhibits the proliferation of HeLa and Raji cancer cells, with IC50 values of 5.07 μM and 1.87 μM, respectively, while exhibiting low toxicity toward non-cancerous Hek293T and DF cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human endocervical adenocarcinoma (HeLa) cells, human Burkitt's lymphoma (Raji) cells, human embryonic kidney (Hek293T) non-cancer cells, primary human dermal fibroblasts (DF) non-cancer cells
-
Concentration:0.1, 1, 10, 50 and 250 μM
-
Incubation Time:72 h
-
Result:Exhibited pronounced antiproliferative activity against HeLa cells with an IC50 of 5.07 μM.
Exhibited pronounced antiproliferative activity against Raji cells with an IC50 of 1.87 μM.
Showed low toxicity against non-cancer Hek293T and DF cells, demonstrating selective cytotoxicity toward malignant cells.
Chemical Information
-
Masse moléculaire 364.44
-
Formule C19H28N2O5
-
SMILES
O=C(OCCCC)C1=CC=C(NC(CCCCCCC(NO)=O)=O)C=C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
HDAC2-IN-4 Related Classifications
HY-187813 Related Classifications
Powered by Bioz